Solvonis Therapeutics plc
SVNS.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -100% | 8.3% | 147.5% | – |
| Gross Profit | £0 | -£0 | -£0 | £0 |
| % Margin | – | -22.8% | -9.4% | 25.1% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | – | -500.5% | -477.5% | -411% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | – | -531.5% | -499.1% | -435.6% |
| EPS Diluted | -0.001 | -0.03 | -0.026 | -0.009 |
| % Growth | 96% | -14.9% | -183.7% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |